Fifteen percent of patients with diabetes mellitus (DM) meet the criteria for comorbid major depression. To maximize response of both depression and diabetic disorder, one should consider antidepressant treatment. The present study compared the efficacy of agomelatine and sertraline in the treatment of symptoms of depression/anxiety, diabetes self-care, and metabolic control in a sample of depressed patients with non-optimally controlled type 2 DM. This was an observational study of 40 depressed patients with DM who were randomly assigned to receive either agomelatine or sertraline, and were assessed over a 4-month period for depression, anxiety, self care, fasting plasma glucose, haemoglobin A1c and body weight. HDRS scores fell at the end of the study for both treatment groups; significantly lower HARS scores were noted at the last assessment for the agomelatine group. Body weight increased slightly in the sertraline group. Although an improvement in fasting plasma glucose was observed in the final assessment in both treatment groups glycated hemoglobin showed a tendency towards lower values in the agomelatine group. JAMAJAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Facial Plastic Surgery JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Kaplan-Meier estimates of the time to recurrence of major depression in patients randomized to treatment with sertraline hydrochloride or placebo. The difference between groups was statistically significant (log-rank test, χMean Beck Depression Inventory (BDI) score at time points during induction and maintenance phases of the study. The recurrence BDI score was calculated for the subset of patients who had a recurrence of major depression during the maintenance phase. levels during the depression-free period of maintenance therapy leading up to recurrence or until the end of the study were not different for all of the subjects from the level at the time of randomization but remained significantly lower than the baseline levels preceding open-label therapy (P = .002). The BDI scores were slightly higher at recovery in the patients treated with sertraline hydrochloride as compared with patients who received placebo but did not differ between groups at the other time points. Outcomes were similar for each treatment arm during maintenance, and the Hb ALustman PJGriffith LSClouse REFreedland KEEisen SARubin EHCarney RMMc Gill JB Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59241- 250Pub Med Google Scholar Crossref Lustman PJGriffith LSFreedland KEKissel SSClouse RE Cognitive behavior therapy for depression in type 2 diabetes: a randomized controlled trial. Ann Intern Med 1998;129613- 621Pub Med Google Scholar Crossref Nielsen BMBehnke KArup PChristiansen PEGeisler AIpsen EMaach-Moller BOhrberg SC A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 1993;87269- 272Pub Med Google Scholar Crossref Keller MBKocsis JHThase MEGelenberg AJRush AJKoran LSchatzberg ARussell JHirschfeld RKlein DMc Cullough JPFawcett JAKornstein SLa Vange LHarrison W Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes The Diabetes and Depression DAD Study. Sep 24, 2013. Researchers at Southampton University believe the pills could be putting hundreds of thousands of people at risk of type 2 diabetes.